In June 2009, there was considerable excitement in the diabetes community when ‘breaking news’ of four epidemiological studies looking at the links between diabetes treatment and cancer were uniquely published collectively in the same issue of the journal Diabetologia. These papers focused the spotlight onto the risk between exogenous insulin therapeutic use, and in particular, that of the insulin analogue, glargine (Lantus), and subsequent cancer development. All four studies had design limitations, and in short, it was not possible to draw firm conclusions. These four studies initially left the diabetes community confused, but positive outcomes then emerged. In 2010, I outlined the first two years of that journey in Diabetes Voice.1
Here, I update the past three years.
Diabetes treatment and cancer - five years after the ‘breaking news’
Submitted by aabolina on Wed, 02/26/2014 - 11:46